Assessing valproate-induced changes in NADH levels in patients with type 2 diabetes using a silver nanoparticle-based...

Area of Science:

• Biochemistry
• Analytical Chemistry
• Metabolic Diseases

Background:

• Type 2 diabetes is linked to increased oxidative stress and altered NAD+/NADH ratio.
• NADH is a critical biomarker for assessing oxidative status in metabolic diseases.

Purpose of the Study:

• To validate a novel spectrophotometric method for quantifying NADH in human plasma.
• To investigate the effect of sodium valproate on NADH levels in type 2 diabetes plasma.

Main Methods:

• Development and validation of a spectrophotometric assay using in-situ silver nanoparticle synthesis for NADH quantification.
• Analysis of NADH levels in plasma samples from type 2 diabetes patients.
• In vitro treatment of plasma samples with varying concentrations of sodium valproate.

Main Results:

• The developed method demonstrated high sensitivity (LOD 0.05 µmol/L⁻¹) and linearity (R² = 0.9965) for NADH detection.
• Intra-day and inter-day precision were acceptable, with RSDs of 4.6% and 7.4%, respectively.
• In vitro sodium valproate treatment led to a dose-dependent decrease in plasma NADH levels.

Conclusions:

• The validated spectrophotometric method provides a reliable tool for NADH quantification in type 2 diabetes research.
• Sodium valproate influences the oxidative status in type 2 diabetes plasma, as evidenced by decreased NADH levels.